Share on StockTwits

AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reaffirmed by research analysts at Deutsche Bank in a report released on Thursday. They currently have a GBX 4,000 ($66.87) price objective on the stock. Deutsche Bank’s target price would suggest a potential downside of 6.65% from the stock’s previous close.

A number of other analysts have also recently weighed in on AZN. Analysts at Jefferies Group reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday. They now have a GBX 4,500 ($75.23) price target on the stock. Separately, analysts at Credit Suisse reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Thursday, August 14th. They now have a GBX 4,800 ($80.24) price target on the stock. Finally, analysts at Societe Generale reiterated a “sell” rating on shares of AstraZeneca plc in a research note on Wednesday, August 13th. They now have a GBX 3,700 ($61.85) price target on the stock. Six analysts have rated the stock with a sell rating, seventeen have issued a hold rating and six have given a buy rating to the company’s stock. AstraZeneca plc presently has an average rating of “Hold” and a consensus price target of GBX 4,055.48 ($67.79).

Shares of AstraZeneca plc (LON:AZN) traded up 2.49% on Thursday, hitting GBX 4391.50. The stock had a trading volume of 1,676,918 shares. AstraZeneca plc has a 52-week low of GBX 3086.50 and a 52-week high of GBX 5750.00. The stock has a 50-day moving average of GBX 4311.87 and a 200-day moving average of GBX 4206.58. The company’s market cap is £55.465 billion.

AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.